ReviewInternational journal of chronic obstructive pulmonary disease2022
Pathological Mechanism and Targeted Drugs of COPD.
Review in International journal of chronic obstructive pulmonary disease, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 96 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
96 citing papers in PubMed, 1 synthesis or guideline pooled it, 131 citations in OpenAlex.
- Association between COPD and CKD: a systematic review and meta-analysis.Frontiers in public health · 2024Pooled it
- Bronchodilator Responsiveness in Preterm-Born Children With Chronic Lung Disease: Importance of Individualized Testing.Pediatric pulmonology · 2026Trial
- Comparing effects of breathing exercises alone and combined with breathing-stretching exercises on respiratory indices, disease severity and exercise capacity in COPD.Scientific reports · 2025Trial
- Reduced contrast agent volume using a heart-rate dependent and free-breathing scanning protocol in coronary computed tomography angiography (CTA) for patients with chronic obstructive pulmonary disease (COPD).BMC cardiovascular disorders · 2025Trial
- Oxidative Stress and Inflammatory Cytokines as Drivers of Cardiac Remodeling in COPD Patients.Antioxidants (Basel, Switzerland) · 2026Article
- Potential Therapeutic Roles of Icariin in Inflammatory Diseases: From Molecular Mechanisms to Clinical Translation Prospects.Antioxidants (Basel, Switzerland) · 2026Review
- Novel Resveratrol Derivatives as Dual PDE4 Inhibitors and Free Radical Scavengers: Rational Design, Synthesis, and Biological Evaluation.Antioxidants (Basel, Switzerland) · 2026Article
- Review of risk factors and prediction models for multidrug-resistant bacterial pulmonary infections in patients with chronic obstructive pulmonary disease.The Journal of international medical research · 2026Review
- Evaluation of squamous cell carcinoma antigen as a diagnostic biomarker in pulmonary diseases: a male cohort study.Diagnostic pathology · 2026Article
- SYVN1-provoked RASA1 ubiquitination promotes pulmonary inflammation in chronic obstructive pulmonary disease.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2026Article
- Multi-Omics Analysis and In Vitro Experimental Validation Identify Candidate Mechanisms of Baicalein Against Chronic Obstructive Pulmonary Disease.Molecules (Basel, Switzerland) · 2026Article
- Article
- Shared molecular signatures between atrial fibrillation and chronic obstructive pulmonary disease: an integrated bioinformatic analysis with experimental validation.BMC medical genomics · 2026Article
- <p>Application of extracellular vesicles in the diagnosis and treatment of chronic obstructive pulmonary disease (Review)</p>.Molecular medicine reports · 2026Review
- SULT1E1 exerts a protective role in COPD by inhibiting the AKT pathway: an in vivo and in vitro study.Scientific reports · 2026Article
- Acacetin Alleviates Cigarette Smoke-Induced Chronic Obstructive Pulmonary Disease in Mice by Inhibiting NLRP3 Inflammasome-Mediated Pyroptosis.Applied biochemistry and biotechnology · 2026Article
- SLC40A1 (iron transporter): mechanistic regulation, role in disease pathogenesis, and prospects for targeted therapy.Frontiers in cell and developmental biology · 2026Review
- Bu-Fei Formula Ameliorates Inflammation in a Preclinical COPD-Like Model by Targeting Mitochondrial Hyperactivity to Inhibit the NLRP3 Inflammasome.International journal of chronic obstructive pulmonary disease · 2026Article
- Beyond pathogens: a narrative review of the immunological nexus of damage-associated molecular patterns and inflammasome activation in sterile AECOPD.Frontiers in immunology · 2026Review
- Research Progress and Comparative Evaluation of Three Cutting-Edge Chronic Obstructive Pulmonary Disease Treatment Strategies: Biologics, Bronchoscopic Lung Volume Reduction, and Stem Cell Therapies.International journal of chronic obstructive pulmonary disease · 2026Review
36 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic obstructive pulmonary disease (COPD) includes chronic bronchitis, emphysema, and small airway obstruction. Incompletely reversible airflow limitation, inflammation, excessive mucus secretion and bronchial mucosal epithelial lesions are the main pathological basis of the disease. The prevalence of COPD is increasingly worldwide, which has caused the burden on individuals and society. This paper summarizes the pathogenesis of COPD and clarifies the effect and mechanism of the latest targeted drugs for COPD. Besides, we focus on NOD-like receptor thermal protein domain associated protein 3 inflammasome (NLRP3 inflammasome). NLRP3 can promote production of interleukin-1β (IL-1β) and interleukin-18 (IL-18). NLRP3 is an important factor in the migratory aggregation of macrophages and neutrophils and the generation of oxidative stress. Inhibition of NLRP3 inflammasome indirectly blocks the inflammatory effects of IL-1β and IL-18, which may be regarded as an ideal target for COPD treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.